Trial Profile
VIVALDI: Valdoxan improves depressive symptoms and normalises circadian rhythms - an observational prospective study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Oct 2022
Price :
$35
*
At a glance
- Drugs Agomelatine (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Therapeutic Use
- Acronyms VIVALDI
- Sponsors Servier
- 09 Oct 2018 Results of a subgroup analysis of VIVALDI and VIVALDI-Praxis studies (n=4394) assessing the safety and efficacy of Agomelatine in depressed patients with comorbid anxiety, presented at the 31st Annual Congress of the European College of Neuropsychopharmacology
- 30 Oct 2010 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 27 May 2009 New trial record